STOCKHOLM, Nov. 19, 2019 /PRNewswire/ -- OssDsign CEO
Anders Lundqvist: "To conclude
it has been a busy and rewarding quarter which has seen the
positive effects of the important investments in the US
organization and transition of the business to OssDsign
USA Inc."
The third quarter in figures
- Net sales amounted to TSEK 4 836 (3 420).
- Loss after taxes amounted to TSEK 19 709 (13 626).
- Loss per share was SEK 1,1
(2,8).
- Cash flow from current operations was TSEK -22 640 (-11
790).
The first 9-months in figures
- Net sales amounted to TSEK 11 804 (9 044).
- Loss after taxes amounted to TSEK 55 379 (39 231).
- Loss per share was SEK 3,8
(8,2).
- Cash flow from current operations was TSEK -47 592 (-39
098).
Important events during the third quarter
- Notification of intention to award contract received from
National Health Service in the UK.
- Number of new accounts in the US increased by 29%.
- First surgeries with CranioPlug in the US, Germany and Sweden.
- OssDsign Cranial reimbursement price confirmed in France and first order received.
- BSI Recertification Assessment successfully conducted.
Important events after the end of the third quarter
- UK National Health Service contract award received.
- OssDsign USA Inc is registered
and listed as importer in the US by the FDA as part of ongoing
transition from US master distributor to OssDsign USA Inc.
- First clinical experience with OssDsign implants on Japanese
patients presented at the annual Japanese neurosurgery meeting in
Osaka.
- The European Patent Office (EPO) granted OssDsign a new
European Patent related to the company's ceramic material
technology.
- FDA clearance for OssDsign Cranial PSI Accessories
received.
- Updated Post Market Surveillance data on the outcome of 670
cranioplasties using OssDsign Cranial PSI are in line with
previously published low rate of complications
Certified Adviser
The Company's Certified Adviser is Erik Penser Bank AB. Contact
information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463-80-00,
email: certifiedadviser@penser.se.
For further information, please contact:
Anders Lundqvist, CEO, OssDsign
AB
Tel: +46-73-206-98-08
email: al@ossdsign.com
About OssDsign
OssDsign is a Swedish medical technology company that develops
and manufactures regenerative implants for improved healing of bone
defects. Providing neuro and plastic surgeons with innovative
implants, OssDsign improves the outcome for patients with severe
cranial and facial defects worldwide. By combining clinical
knowledge with proprietary technology, OssDsign manufactures and
sells a growing range of patient-specific solutions for treating
cranial defects and facial reconstruction. OssDsign's technology is
the result of collaboration between clinical researchers at
Karolinska University Hospital in Stockholm and material scientists at the
Ångström Laboratory at Uppsala
University.
This information is information that OssDsign AB is obliged
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication through the agency of the
contact person set out above, at 08:00
CET on November 19th,
2019
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/ossdsign-ab/r/ossdsign-ab--publ--publishes-q3-2019-interim-report,c2967344
The following files are available for download:
https://mb.cision.com/Main/18020/2967344/1146386.pdf
|
OssDsign AB Interim
Report for the third quarter of 2019
|